NR4A1 and breast carcinoma: In human breast cancers, PIK3CA mutations are more frequent in hormone receptor-positive/HER2-negative tumors (around 42%), typically low-grade, and less common in higher-grade triple-negative breast cancers (approximately 16%)24.